Background: To inform the development of interventions to retain donors following a vasovagal reaction (VVR), the aim of this study is to use the Health Action Process Approach (HAPA) to identify predictors of intentions to re-donate and actual return behavior among whole blood (WB) and plasma donors who experienced a VVR.

Study Design And Methods: A total of 1136 WB donors (M  = 32.4 ± 12.5 years; 73.4% female) and 1141 plasma donors (M  = 36.5 ± 14.4 years; 73.3% female) completed an online survey after experiencing a VVR. Two hierarchical regression analyses were conducted for each donation type. In the first analysis, donation intentions were regressed onto the motivational HAPA constructs and social support. In the second analysis, donor return within 6 months was regressed onto social support, intentions, and the volitional HAPA constructs.

Results: The motivational and social support variables accounted for 47.2% of the variance in intentions to return in WB donors and 15.7% in plasma donors. For both groups, task self-efficacy, positive and negative outcome expectancies, and social support were significant predictors of intentions to return. Intentions and action planning were significant predictors of donor return in both groups, and recovery self-efficacy was significant for plasma only.

Conclusion: The HAPA model can provide guidance to blood collection agencies to design phase-specific and individually-focused interventions to retain WB and plasma donors following a VVR.

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.17052DOI Listing

Publication Analysis

Top Keywords

plasma donors
20
social support
16
intentions return
12
health action
8
action process
8
process approach
8
donation intentions
8
return behavior
8
vasovagal reaction
8
blood plasma
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Alamar Biosciences, Fremont, CA, USA.

Background: The development of reliable blood biomarkers for neurodegenerative diseases (NDDs) has been hindered by the lack of tools with sufficient sensitivity to detect low concentrations of brain-derived proteins in plasma or serum in a highly multiplexed manner. NULISA™ (NUcleic acid-Linked Immuno-Sandwich Assay) has emerged as a promising solution, with attomolar sensitivity and capable of high multiplexing in a fully automated system. In this study, we introduce NULISA CNS Disease Panel 120, a 120-plex NULISAseq assay for profiling key hallmarks of NDDs in both blood and cerebrospinal fluid (CSF).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Labcorp Central Laboratories, Indianapolis, IN, USA.

Background: Alzheimer's Disease (AD) is a major neurodegenerative disorder characterized by amyloid deposits in brain tissues and representing a continuously increasing global burden in need of disease-modifying therapeutic options. Amyloid beta 1-42 and 1-40 peptides and the amyloid beta 1-42/1-40 ratio are hallmarks of AD and are commonly monitored in Cerebro-Spinal Fluid (CSF) along other AD biomarkers, to support diagnosis and management of AD patients. Over the past few years, blood-based AD biomarkers have emerged as highly relevant and more practical alternatives to CSF biomarkers, and further technical performance characterization of the associated assays would be beneficial to the AD research and medical community.

View Article and Find Full Text PDF

Background: Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy specific to individuals with repetitive head trauma. Traumatic encephalopathy syndrome (TES) is the proposed clinical syndrome resulting from CTE with or without other contributing neuropathologies. Pathophysiological mechanisms driving CTE and underlying TES symptoms are not understood.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Sanofi, Cambridge, MA, USA.

Background: One hypothesis of lack of effectiveness in most current clinical trials for the AD (Alzheimer's disease) is the advanced stages of the disease at the time of pharmacological intervention. To aim a robust effect from disease-modifying therapies, there is an urgent need for biomarkers that can identify patients with MCI and early stages of AD. In this study, we combined in-house large-scale LC-MS and new emerging highly sensitive NULISA proteomics analysis on a medium sized AD cohort sample, aiming an early-stage protein biomarker discovery in MCI and AD.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

ADx NeuroSciences NV, Ghent, Belgium.

Background: Among the different phospho-tau sites, phosphorylation at Threonine 205 (pTau205) in CSF has been shown to be closely associated with Tau-PET (Lantero-Rodriguez et al. 2024; Barthélemy et al. 2023).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!